ArticleJournal of medical case reports2025
Refractory ventricular tachyarrhythmias following entrectinib initiation in metastatic lung adenocarcinoma: a case report.
Article in Journal of medical case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundEntrectinib is a targeted therapy that has been approved for the treatment of ROS1-positive non-small cell lung cancer. However, this therapy is associated with known but rare cardiotoxic risks. CASE PRESENTATION: We report a case of ventricular tachyarrhythmias occurring on day 4 after entrectinib initiation in a 37-year-old Han Chinese man with ROS1-positive metastatic lung adenocarcinoma. The arrhythmias was refractory to pharmacologic and electrical therapy, resulting in hemodynamic collapse and the need for venoarterial extracorporeal membrane oxygenation. The diagnostic workup excluded other causes, and therapeutic plasma exchange led to rhythm stabilization and cardiac recovery. The patient was successfully weaned from extracorporeal membrane oxygenation by day 5.
conclusionsThis case highlights a potentially fatal early-phase cardiac complication of entrectinib and supports the use of early electrocardiographic monitoring and therapeutic plasma exchange as management and rescue strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.